Decreased Dromotropic Response to Verapamil Despite Pronounced Increased Drug Concentration in Rheumatoid Arthritis

Overview

Journal Br J Clin Pharmacol

Specialty Pharmacology

Date 2001 Jan 3

PMID 11136300

Citations 30

Authors

P R Mayo

K Skeith

A S Russell

F Jamali

Affiliations

Soon will be listed here.

Abstract

Aims: Inflammation reduces hepatic clearance of many drugs with unknown therapeutic consequences. This study was carried out to examine the effect of rheumatoid arthritis (RA) on the pharmacokinetics and pharmacodynamics of verapamil.

Methods: Eight RA patients were age- and sex-matched with eight healthy volunteers. The disease severity was assessed, and ECG, blood pressure and verapamil enantiomers concentrations were measured for 12 h post 80 mg oral verapamil. Serum interleukin-6 (IL-6) and nitrite (NO2-) were measured in predose samples.

Results: IL-6 and NO2- concentrations were significantly increased in parallel with disease severity. Oral clearance of both S- and R-verapamil was significantly decreased by RA. While the unbound fraction of S- and R-verapamil decreased by 5 and 7-fold, respectively, the unbound AUC remained unchanged for the more potent enantiomer, S-verapamil. AUC of norverapamil enantiomers was increased 2-3-fold. Despite elevated serum drug concentrations in RA, the potential to prolong the PR-interval was significantly reduced by one fold and the effect on the heart rate and blood pressure did not increase.

Conclusions: RA results in increased verapamil concentrations due likely to changes in protein binding, decreased clearance and/or altered hepatic blood flow. A significant decrease in dromotropic effect, despite increased serum drug concentrations, may be attributed to receptor down regulation caused by pro-inflammatory cytokines and/or NO.

Citing Articles

Evaluation of the Effect of Risankizumab on the Pharmacokinetics of Cytochrome P450 Substrates in Patients with Moderately to Severely Active Ulcerative Colitis or Crohn's Disease.

DCunha R, Azam T, Kalabic J, Anschutz T, Lahat A, Pang Y Clin Pharmacokinet. 2024; 64(1):143-154.

PMID: 39707077 PMC: 11762434. DOI: 10.1007/s40262-024-01462-4.

Applications of the Cholesterol Metabolite, 4β-Hydroxycholesterol, as a Sensitive Endogenous Biomarker for Hepatic CYP3A Activity Evaluated within a PBPK Framework.

Karkhanis A, Harwood M, Stader F, Bois F, Neuhoff S Pharmaceutics. 2024; 16(10).

PMID: 39458613 PMC: 11510160. DOI: 10.3390/pharmaceutics16101284.

The Impact of Paediatric Obesity on Drug Pharmacokinetics: A Virtual Clinical Trials Case Study with Amlodipine.

Burhanuddin K, Mohammed A, Badhan R Pharmaceutics. 2024; 16(4).

PMID: 38675150 PMC: 11053426. DOI: 10.3390/pharmaceutics16040489.

Drug-disease interaction: Clinical consequences of inflammation on drugs action and disposition.

Abdallah Y, Chahal S, Jamali F, Mahmoud S J Pharm Pharm Sci. 2023; 26:11137.

PMID: 36942294 PMC: 9990632. DOI: 10.3389/jpps.2023.11137.

Advancing personalized medicine for tuberculosis through the application of immune profiling.

Thu V, Dat L, Jayanti R, Trinh H, Hung T, Cho Y Front Cell Infect Microbiol. 2023; 13:1108155.

PMID: 36844400 PMC: 9950414. DOI: 10.3389/fcimb.2023.1108155.

References

Arend W, Dayer J . Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum. 1990; 33(3):305-15. DOI: 10.1002/art.1780330302. View

Houston M . Nonsteroidal anti-inflammatory drugs and antihypertensives. Am J Med. 1991; 90(5A):42S-47S. DOI: 10.1016/0002-9343(91)90485-g. View

Johnson K, Balderston S, Pieper J, Mann D, Reiter M . Electrophysiologic effects of verapamil metabolites in the isolated heart. J Cardiovasc Pharmacol. 1991; 17(5):830-7. DOI: 10.1097/00005344-199105000-00020. View

Shibukawa A, Wainer I . Simultaneous direct determination of the enantiomers of verapamil and norverapamil in plasma using a derivatized amylose high-performance liquid chromatographic chiral stationary phase. J Chromatogr. 1992; 574(1):85-92. DOI: 10.1016/0378-4347(92)80101-u. View

Baerwald C, Graefe C, von Wichert P, Krause A . Decreased density of beta-adrenergic receptors on peripheral blood mononuclear cells in patients with rheumatoid arthritis. J Rheumatol. 1992; 19(2):204-10. View

Finkel M, Oddis C, Jacob T, Watkins S, HATTLER B, Simmons R . Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science. 1992; 257(5068):387-9. DOI: 10.1126/science.1631560. View

Piquette-Miller M, Jamali F . Effect of adjuvant arthritis on the disposition of acebutolol enantiomers in rats. Agents Actions. 1992; 37(3-4):290-6. DOI: 10.1007/BF02028122. View

Piquette-Miller M, Jamali F . Selective effect of adjuvant arthritis on the disposition of propranolol enantiomers in rats detected using a stereospecific HPLC assay. Pharm Res. 1993; 10(2):294-9. DOI: 10.1023/a:1018907431893. View

Abernethy D, Wainer I, Longstreth J, Andrawis N . Stereoselective verapamil disposition and dynamics in aging during racemic verapamil administration. J Pharmacol Exp Ther. 1993; 266(2):904-11. View

10.

Murad F, Forstermann U, Nakane M, Pollock J, Tracey R, Matsumoto T . The nitric oxide-cyclic GMP signal transduction system for intracellular and intercellular communication. Adv Second Messenger Phosphoprotein Res. 1993; 28:101-9. View

11.

Loyer P, Fautrel A, GAUTIER J, Corcos L, Turlin B, Beaune P . Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. Mol Pharmacol. 1993; 44(4):707-15. View

12.

Kroemer H, GAUTIER J, Beaune P, Henderson C, Wolf C, Eichelbaum M . Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993; 348(3):332-7. DOI: 10.1007/BF00169164. View

13.

Khatsenko O, Gross S, Rifkind A, Vane J . Nitric oxide is a mediator of the decrease in cytochrome P450-dependent metabolism caused by immunostimulants. Proc Natl Acad Sci U S A. 1993; 90(23):11147-51. PMC: 47939. DOI: 10.1073/pnas.90.23.11147. View

14.

DePetrillo P, Abernethy D, Wainer I, Andrawis N . Verapamil decreases lymphocyte protein kinase C activity in humans. Clin Pharmacol Ther. 1994; 55(1):44-9. DOI: 10.1038/clpt.1994.8. View

15.

Chen Y, Le Vraux V, Leneveu A, Dreyfus F, Stheneur A, Florentin I . Acute-phase response, interleukin-6, and alteration of cyclosporine pharmacokinetics. Clin Pharmacol Ther. 1994; 55(6):649-60. DOI: 10.1038/clpt.1994.82. View

16.

Laethem M, Belpaire F, Wijnant P, Rosseel M, Bogaert M . Influence of endotoxin on the stereoselective pharmacokinetics of oxprenolol, propranolol, and verapamil in the rat. Chirality. 1994; 6(5):405-10. DOI: 10.1002/chir.530060508. View

17.

Piquette-Miller M, Jamali F . Influence of severity of inflammation on the disposition kinetics of propranolol enantiomers in ketoprofen-treated and untreated adjuvant arthritis. Drug Metab Dispos. 1995; 23(2):240-5. View

18.

Johnson J, Akers W . Influence of metabolites on protein binding of verapamil enantiomers. Br J Clin Pharmacol. 1995; 39(5):536-8. PMC: 1365062. DOI: 10.1111/j.1365-2125.1995.tb04492.x. View

19.

Myers S, Turnage R, Hernandez R, CASTENADA A, Valentine R . Autoregulation of renal and splanchnic blood flow following infra-renal aortic clamping is mediated by nitric oxide and vasodilator prostanoids. J Cardiovasc Surg (Torino). 1996; 37(2):97-103. View

20.

Pietila K, Harmoinen A, Jokiniitty J, Pasternack A . Serum C-reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic treatment. Eur Heart J. 1996; 17(9):1345-9. DOI: 10.1093/oxfordjournals.eurheartj.a015068. View